Dexcom (Nasdaq:DXCM) announced today that it appointed Dr. Euan Ashley to its board of directors, effective Oct. 24, 2025. Ashley, a renowned researcher, entrepreneur and clinician, brings extensive leadership experience across healthcare research institutions and private organizations. He currently serves as chair of the Dept. of Medicine at Stanford Health. Research areas for Ashley span […]
Diabetes
Vivani prices $15.7M offering
Vivani Medical (Nasdaq:VANI) announced that it priced a best efforts registered direct offering of 6 million shares of common stock. The Alameda, California-based company priced the shares at $1.62 apiece. It also announced a concurrent private placement of more than 3.7 million shares of common stock at the same price. Gregg Williams, the company’s board […]
Insulet adds JPMorgan veteran to its board of directors
Insulet (Nasdaq:PODD) announced today that it appointed Robert “Robbie” L. Huffines to its board of directors. Huffines, a former global chair of investment banking at JPMorgan Chase & Co., joins the automated insulin delivery technology maker’s board effective Oct. 31, 2025. He joins as an independent director and a member of the Insulet Audit Committee. […]
Abbott makes Lingo OTC CGM available for sale at Walmart
Abbott (NYSE:ABT) today shared that it made its Lingo biowearable device available for purchase at Walmart stores. This marks the first availability for the over-the-counter continuous glucose monitor (CGM) at a brick-and-mortar retailer. It brings the Lingo device to more than 3,500 Walmart Supercenter locations (in their health and wellness sections) in the U.S. and […]
Dexcom is facing a class action suit related to G7 CGM
A class action lawsuit has been filed against Dexcom (Nasdaq:DXCM) in the U.S. District Court for the Central District of California. The lawsuit, led by plaintiff Kelly Grisoli on behalf of all others similarly situated, demands a jury trial for claims that Dexcom’s representations for its latest-generation G7 continuous glucose monitor (CGM) were false, misleading, […]
Civica to launch affordable long-acting insulin in pre-filled pens in 2026
Civica announced today that it plans to launch an affordable long-acting insulin in pre-filled pens starting in January 2026. The company plans to launch insulin glargine-yfgn in pre-filled pens at the lowest list price in the current long-acting insulin market. It intends to make the offering available in the U.S. beginning on Jan. 1, 2026. […]
Abbott CEO expects continued growth in Diabetes Care with Libre 3, dual sensor
Abbott (NYSE:ABT) continues to get a boost in its Medical Devices business from its Diabetes Care unit’s portfolio of continuous glucose monitors (CGMs). In the company’s third-quarter earnings report released today, Abbott — one of the largest medtech companies in the world — fell shy of Wall Street’s sales expectations, but still reported more than 15% […]
Tandem says Abbott FreeStyle Libre 3 integration is ‘coming soon’
On social media, Tandem Diabetes Care (Nasdaq:TNDM) said the launch of a new integration for its insulin pump system is near. “It’s almost here! The t:slim X2 insulin pump integration with the FreeStyle Libre 3 Plus sensor, the world’s smallest continuous glucose monitor, is coming soon,” Tandem wrote on LinkedIn. Tandem announced that it was […]
FDA accepts application for MannKind inhaled insulin in kids
MannKind (Nasdaq:MNKD) announced today that the FDA accepted a supplemental biologics license for its Afrezza inhaled insulin. The submission, if ultimately approved, would enable MannKind to bring Afrezza to children and adolescents (aged 4-17). Afrezza is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to slowly bring powder […]
Sequel twiist developer DEKA acquires assets, IP from Diatech Diabetes
Diatech Diabetes announced today that DEKA Research & Development acquired its core assets and intellectual property (IP). DEKA, the firm behind the Sequel Med Tech twiist automated insulin delivery system, developed the underlying drug delivery technology for the recently launched pump. Dean Kamen, co-founder of Sequel and founder of DEKA, commercialized the first wearable insulin […]
